Natalia E. Lugovska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Natalia E. Lugovska has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrew V. Rebriev
National Academy of Sciences of Ukraine
2 shared publications - Denys Leonidovych Kolesnyk
Department of Metastasis Pathophysiology, R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine
2 shared publications - Galina Ivanivna Solyanik
Department of Metastasis Pathophysiology, R. E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of the National Academy of Sciences of Ukraine, Kyiv 03022, Ukraine
2 shared publications - Olga N. Pyaskovskaya
National Academy of Sciences of Ukraine
2 shared publications - Rostyslav Y. Marunych
National Academy of Sciences of Ukraine
2 shared publications - Tetiana V. Kozytska
PhD in Biological Sciences, Associate Professor, Department of Chemistry, Faculty of Natural Sciences, National University of “Kyiv-Mohyla Academy”, Kyiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by AOSIS in Journal of Medicinal Plants for Economic Development
- Vol. 10 (1) , 1
Corrigendum: The impact of extract of mistletoe on tumour cells and hemostasis of human plasma
Journal of Medicinal Plants for Economic Development
- 1 January 2026
- Published by AOSIS in Journal of Medicinal Plants for Economic Development
- Vol. 10 (1) , 1
Open AccessCorrigendum: The impact of extract of mistletoe on tumour cells and hemostasis of human plasma
Journal of Medicinal Plants for Economic Development
- Open Access
- 8 February 2023
- Published by AOSIS in Journal of Medicinal Plants for Economic Development
- Vol. 7 (1)
The impact of extract of mistletoe on tumour cells and hemostasis of human plasma
Background: The plant Viscum album (Mistletoe) is a known source of biologically active substances, used in traditional medicine in Europe and Asia.Aim: The goal was to study cytotoxic/cytostatic effect of mistletoe extract on tumour and normal cells and its influences on certain proteins of the blood coagulation system.Setting: Mistletoe was collected in Ukraine in November 2020.Methods: Water extract of V. album, both leaves and stems, was obtained and fractionated; it was characterised using high-performance liquid chromatography (HPLC) and mass spectrometry and tested on cancer cells and blood plasma.Results: Extract demonstrated the presence of viscotoxins and carbohydrates and thermolabile compounds that enhance the activity of thrombin and factor X in plasma in the presence of calcium ions and increased the activated partial thromboplastin time (APTT) by 2.7 times. The cytotoxic/cytostatic action of the mistletoe fractions, the total extract and the fraction 10 000 Da were higher in relation to Lewis lung carcinoma (LLC) cells than with Vero cells. The IC50 of total extract for LLC cells was 35% (p 0.05) lower than that for Vero cells (1.12 ± 0.2 and 1.71 ± 0.15 mg/ml). Thus, the IC50 of the fraction 10 000 Da for LLC cells was more than by 44% (p 0.05) lower than that for Vero cells (2.07 ± 0.26 and 3.67 ± 0.41 mg/ml).Conclusion: It was shown that both extracts exhibited a cytotoxic/cytostatic effect, more pronounced against tumour cells than normal cells and enhanced the clotting of blood plasma by thermolabile compounds by facilitating plasma coagulation.Contribution: This research makes it possible to study mistletoe as a light and cheap anticancer therapy plant and cure blood coagulopathy or construct antibleeding bandages.
- 8 February 2023
- Published by AOSIS in Journal of Medicinal Plants for Economic Development
- Vol. 7 (1)
Open AccessThe impact of extract of mistletoe on tumour cells and hemostasis of human plasma
Background: The plant Viscum album (Mistletoe) is a known source of biologically active substances, used in traditional medicine in Europe and Asia.Aim: The goal was to study cytotoxic/cytostatic effect of mistletoe extract on tumour and normal cells and its influences on certain proteins of the blood coagulation system.Setting: Mistletoe was collected in Ukraine in November 2020.Methods: Water extract of V. album, both leaves and stems, was obtained and fractionated; it was characterised using high-performance liquid chromatography (HPLC) and mass spectrometry and tested on cancer cells and blood plasma.Results: Extract demonstrated the presence of viscotoxins and carbohydrates and thermolabile compounds that enhance the activity of thrombin and factor X in plasma in the presence of calcium ions and increased the activated partial thromboplastin time (APTT) by 2.7 times. The cytotoxic/cytostatic action of the mistletoe fractions, the total extract and the fraction 10 000 Da were higher in relation to Lewis lung carcinoma (LLC) cells than with Vero cells. The IC50 of total extract for LLC cells was 35% (p 0.05) lower than that for Vero cells (1.12 ± 0.2 and 1.71 ± 0.15 mg/ml). Thus, the IC50 of the fraction 10 000 Da for LLC cells was more than by 44% (p 0.05) lower than that for Vero cells (2.07 ± 0.26 and 3.67 ± 0.41 mg/ml).Conclusion: It was shown that both extracts exhibited a cytotoxic/cytostatic effect, more pronounced against tumour cells than normal cells and enhanced the clotting of blood plasma by thermolabile compounds by facilitating plasma coagulation.Contribution: This research makes it possible to study mistletoe as a light and cheap anticancer therapy plant and cure blood coagulopathy or construct antibleeding bandages.
- 14 February 2022
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Science and innovation
- Vol. 18 (1) , 66-75
РОЗРОБЛЕННЯ ЗАСОБУ ДЛЯ ПОКРАЩЕННЯ КОГНІТИВНИХ ФУНКЦІЙ ТА ЗНИЖЕННЯ РІВНЯ ГОМОЦИСТЕЇНУ
Introduction. Hyperhomocysteinemia is a dangerous metabolic disorder that leads to a number of diseases. Problem Statement. Urgent task is to develop pharmaceutical product for lowering the homocysteine levels without causing side effects. Purpose. To develop the dietary supplement for reducing high homocysteine levels, which has a minimum content of components that may cause side effects; to test the supplement effect on the cognitive abilities of animals and to commercialize the product. Materials and Methods. The developed dietary supplement Alfacognitin contains vitamins B6, B9, B12, C, and choline. For modelling experimental hyperhomocysteinemia in rats, the animals are kept on a diet rich in L-methionine. Blood homocysteine concentrations are determined by the ion exchange liquid column chromatography method with the use of an automatic amino acid analyzer. The behavioral responses and cognitive abilities of the rats have been studied with the use of behavioral tests (open field test, fear conditioning test, and social int e raction test). The production of Alfacognitin dietary supplement has been launched with Nutrimed Ltd. (Kyiv). Results. Alfacognitin has been shown to reduce homocysteine levels, to improve cognitive abilities, social interaction and communication skills, and to compensate functional memory and learning disorders in animals with hyperhomocysteinemia. Specifications for the dietary supplement have been approved, a pilot technology for obtaining the capsule form of the drug has been developed, and an experimental batch has been manufactured. Conclusions. Alfacognitin may reduce the homocysteine levels. Therefore, it may be used to normalize the functional state of the cardiovascular and nervous systems in patients with hyperhomocysteinemia, as well as to improve the cognitive functions, in particular in patients after COVID-19.
- 14 February 2022
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Science and innovation
- Vol. 18 (1) , 66-75
РОЗРОБЛЕННЯ ЗАСОБУ ДЛЯ ПОКРАЩЕННЯ КОГНІТИВНИХ ФУНКЦІЙ ТА ЗНИЖЕННЯ РІВНЯ ГОМОЦИСТЕЇНУ
Introduction. Hyperhomocysteinemia is a dangerous metabolic disorder that leads to a number of diseases. Problem Statement. Urgent task is to develop pharmaceutical product for lowering the homocysteine levels without causing side effects. Purpose. To develop the dietary supplement for reducing high homocysteine levels, which has a minimum content of components that may cause side effects; to test the supplement effect on the cognitive abilities of animals and to commercialize the product. Materials and Methods. The developed dietary supplement Alfacognitin contains vitamins B6, B9, B12, C, and choline. For modelling experimental hyperhomocysteinemia in rats, the animals are kept on a diet rich in L-methionine. Blood homocysteine concentrations are determined by the ion exchange liquid column chromatography method with the use of an automatic amino acid analyzer. The behavioral responses and cognitive abilities of the rats have been studied with the use of behavioral tests (open field test, fear conditioning test, and social int e raction test). The production of Alfacognitin dietary supplement has been launched with Nutrimed Ltd. (Kyiv). Results. Alfacognitin has been shown to reduce homocysteine levels, to improve cognitive abilities, social interaction and communication skills, and to compensate functional memory and learning disorders in animals with hyperhomocysteinemia. Specifications for the dietary supplement have been approved, a pilot technology for obtaining the capsule form of the drug has been developed, and an experimental batch has been manufactured. Conclusions. Alfacognitin may reduce the homocysteine levels. Therefore, it may be used to normalize the functional state of the cardiovascular and nervous systems in patients with hyperhomocysteinemia, as well as to improve the cognitive functions, in particular in patients after COVID-19.